Compare BMHL & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMHL | MXCT |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.4M | 86.5M |
| IPO Year | N/A | 2021 |
| Metric | BMHL | MXCT |
|---|---|---|
| Price | $3.75 | $0.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 1.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,627,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.64 |
| P/E Ratio | $66.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $0.64 |
| 52 Week High | $4.48 | $3.58 |
| Indicator | BMHL | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 34.49 |
| Support Level | $3.31 | $0.75 |
| Resistance Level | $3.91 | $1.79 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 29.27 | 67.86 |
Bluemount Holdings Ltd through its operating subsidiaries, it is a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces. The financial services includes underwriting and placing services, securities dealing and brokerage services, and asset management services. It provides comprehensive consulting and advisory services on business development strategies to its diverse clientele. Generally, the company provides consulting and advisory business for the following segments: Corporate Finance; and Strategic Communications.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.